ロード中...
Bisphosphonates and other bone agents for breast cancer
BACKGROUND: Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast‐mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast...
保存先:
| 出版年: | Cochrane Database Syst Rev |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Ltd
2017
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6485886/ https://ncbi.nlm.nih.gov/pubmed/29082518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD003474.pub4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|